ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Press Release
https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g
FREMONT, CA, Feb. 27, 2024 ABVC BioPharma Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination…
read more